Established in 2020, this company operates two premium supplement brands targeting women seeking a natural alternative to prescription stimulants and the 40+ demographic seeking heart health. With exceptional 71% TTM growth and 60% gross margins, both brands leverage unified marketing, fulfillment, and customer operations for efficient growth. The company is implementing sustainable packaging, representing a retroactive reduction in shipping costs of ~$700K annually (not in the P&L), providing immediate built-in equity. They maintain premium positioning with elevated packaging, sub-20-minute response times, and clinically validated formulations manufactured in FDA-registered US facilities.

The business delivers exceptional financial performance via predictable subscription revenue, with 55%–60% of sales generating $1.05M combined MRR. Strong customer retention drives an impressive lifetime value (LTV) of $215. The company achieves remarkable cash-flow dynamics through net 120-day supplier terms while collecting payments within 1-3 weeks, resulting in a strong negative cash conversion cycle that funds growth without needing external capital.

Competitive differentiation centers on formulations designed to match clinical-study dosage levels, addressing industry-wide underdosed ingredients. The business demonstrates exceptional scalability and efficiency. Marketing spend has increased from $250K to $650K/mth while maintaining strong margins, reaching $3.4M SDE, and achieving and a 12% TTM reduction in ad spend as a percentage of revenue.

The acquisition presents immediate expansion opportunities beyond proven digital channels. Major retail chains, including Walgreens, CVS, and Whole Foods, offer significant growth potential. The proven infrastructure creates a ready platform for additional brands, while international markets remain untapped. The founder is committed to a smooth transition and prefers retaining a meaningful minority stake to support ongoing growth.

Key Benefits:

Predictable Revenue: With ~60% of total revenue coming from subscriptions, the company generates $1.05M in MRR. Combined with a $215 customer LTV and 50% MRR growth in just six months, the business demonstrates stability and strong momentum.

Superior Cash-Flow Dynamics: Suppliers are paid 10% down with 120-day terms while collecting from customers within days, creating a powerful negative cash conversion cycle and enabling self-funded growth to $3M+ in earnings with no outside capital.

Dual-Brand Operational Synergies: A proven dual-brand strategy creates operational synergies and economies of scale across marketing, fulfillment, and customer service while providing diversification across target demographics.

Superior Unit Economics: YoY SDE growth of 158% on 71% revenue growth, combined with ~60% gross margins and improvement in marketing efficiency (down 12% as a percentage of revenue), has proven their model where scale amplifies profitability.

FDA-Registered US Manufacturing: Quality-assured production in FDA-registered facilities with established US-based supplier relationships and backup manufacturing capacity ensures consistent product availability and regulatory compliance.

Desire for Retained Equity: Well-documented operational systems are updated annually. The founders are committed to a smooth transition, evidenced by their willingness to provide ample training and their desire to retain meaningful minority equity.